In-silico studies for targeting PPARγ for the Type II Diabetes Mellitus. (2022)

• Record Type: Journal Article
• Authors: Reetu, Reetu; Garg, Aakriti; Roy, Kuldeep K.; Roy, Anupam; Gupta, Sreya; Malakar, Chandi C.
• Is Part Of: Materials today. Volume 57:Part 1(2022)
• Page Start: 44
• Page End: 48
• Publication Date: 2022
• Subjects: PPAR-γ -- Type 2 diabetes mellitus -- In-silico study -- Ligand binding domain -- Docking study; Materials science -- Congresses -- Periodicals; 620.1
• DOI: 10.1016/j.matpr.2022.01.299
• Languages: English
• ISSNs: 2214-7853

Abstract

Graphical abstract: Abstract: The virtual molecular library contains phenolic group at the intermediate stage was investigated which having a potency to treat Type 2 Diabetes Mellitus. The designed molecules have shown comparable in-silico binding affinity to marketed thiazolidinedione (TZD) class of drug toward peroxisome proliferator activated receptor-γ (PPAR-γ) protein. Interestingly, change of phenolic group with 5-hydroxy quinolone in pioglitazone has shown high structural conservation in PPAR-γ ligand binding domain (LBD) with pioglitazone having better affinity. This information might be very useful to identify novel lead compounds for further development toward Type 2 Diabetes Mellitus treatment targeting PPAR-γ.